Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)

Drug Reaction with eosinophilia and Systemic Symptoms (DRESS) is a rare and severe multiorgan drug reaction whose pathophysiological mechanisms underlying remain unclear, but may involve the role of several immune cells like eosinophils. iIndeed,the number of eosinophils is increased in blood and/or in organs tiisues in at least 50% of patients with DRESS. There is no specific treatment available. The standard of care is corticosteroids, but they may be inefficient or poorly tolerated. The aim of this research is to find out whether a specific treatment of the immunological response in DRESS syndrome would be useful in combination with corticosteroids to speed up the recovery from DRESS syndrome and therefore reduce the total length of your hospital stay when your illness is being managed. This a multicenter, international, prospective, interventional study, double-blinded, placebo-controlled, randomized, in two balanced parallel groups, one receiving the standard of care (topical or systemic corticosteroids, according to the severity of DRESS syndrome) and the other one corticsoteroids and a targeted therapy against eosinophils (benralizumab, already available in other eosinophilic diseases like asthma).

Start Date06 Jan 2025

Sponsor / Collaborator

AstraZeneca PLC

NCT06512883 / Not yet recruitingPhase 3

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab.

Start Date31 Dec 2024

Sponsor / Collaborator

AstraZeneca PLC

CTR20242248 / RecruitingPhase 3

一项在嗜酸性粒细胞增多综合征（HES）患者中评价Benralizumab的有效性和安全性的多中心、随机、双盲、平行组、安慰剂对照、24周、III期研究（包含开放性扩展期）

[Translation] A multicenter, randomized, double-blind, parallel-group, placebo-controlled, 24-week, phase III study (including an open-label extension phase) to evaluate the efficacy and safety of benralizumab in patients with hypereosinophilic syndrome (HES)

评价Benralizumab对嗜酸性粒细胞增多综合征（HES）患者的有效性和安全性

[Translation]

To evaluate the efficacy and safety of benralizumab in patients with hypereosinophilic syndrome (HES)

Start Date02 Sep 2024

Sponsor / Collaborator

AstraZeneca AB

[+2]

100 Clinical Results associated with Benralizumab

100 Translational Medicine associated with Benralizumab

100 Patents (Medical) associated with Benralizumab

797

Literatures (Medical) associated with Benralizumab

01 Jan 2025·Respiratory Investigation

Biologics treatment for eosinophilic chronic rhinosinusitis complicated by bronchial asthma: Narrative review

Review

Author: Nagano, Tatsuya

There are 4 subtypes of chronic rhinosinusitis (CRS): eosinophilic CRS with nasal polyps (ECRSwNP), ECRS without NPs (ECRSsNP), non-ECRSwNP, and non-ECRSsNP. Most ECRS cases are categorized as ECRSwNP, and the number of patients with ECRSwNP has recently increased. ECRS is associated mainly with helper T-cell type 2 inflammation and eosinophils. Recently, Interleukin-25, -33, or TSLP, helper T-cell type 17, and Group 2 innate lymphoid cells have also been shown to be involved in the molecular mechanism of ECRS. ECRS can lead to several complications including bronchial asthma and/or aspirin intolerance. Conventionally, surgery and corticosteroids have been used to treat ECRS, but biologics have since been applied. Mepolizumab, benralizumab, and tezepelumab have been reported to improve asthma complicated by NPs more than asthma uncomplicated by NPs. Omalizumab, mepolizumab, benralizumab, and dupilumab have been reported to significantly improve Sinonasal Outcome Test-22 scores, nasal polyp scores, and nasal congestion severity in phase III trials. Benralizumab, dupilumab, and tezepelumab have been reported to improve both ECRS and complicated bronchial asthma.

01 Jan 2025·JOINT BONE SPINE

Update on targeted treatments for ANCA-associated vasculitis

Article

Author: Puéchal, Xavier

Targeted therapy has revolutionized the management of ANCA-associated vasculitis (AAV) over the last fifteen years. Rituximab, an approved induction and maintenance agent for severe AAV, is no less effective than cyclophosphamide as induction therapy and particularly useful in relapsing or refractory disease, or in women. In patients with relapsing AAV, granulomatosis with polyangiitis or PR3-ANCA, it is more effective than cyclophosphamide. Rituximab maintenance is superior to the conventional immunosuppressive drugs that it replaces. Low-dose preemptive rituximab infusions are recommended every 6months for 18months, followed by re-evaluation to decide whether 4 additional biannual infusions should be administered, balancing the probability of relapse and the risk of serious infections on rituximab. A growing body of experimental and clinical data shows that C5a pathway inhibition is a promising therapeutic option for AAV, which could reduce glucocorticoids needs. Avacopan is a first approved oral C5A receptor antagonist, used when there is a high risk that glucocorticoids will cause serious adverse events. In eosinophilic granulomatosis with polyangiitis, the importance of IL-5 for eosinophil activation and survival led to evaluation and approval of mepolizumab, a humanized monoclonal antibody directed against IL-5. Mepolizumab showed a steroid-sparing effect. Its effectiveness in active vasculitis remains uncertain and is currently being evaluated. Benralizumab targeting the IL-5 receptor was recently shown to be noninferior to mepolizumab. Rituximab has had disappointing results in non-severe active vasculitis and is being evaluated as maintenance therapy. Plasma exchange is not indicated as first-line treatment but remains recommended when creatinine levels exceed 300μmol/L.

31 Dec 2024·Annals of medicine

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis

Article

Author: Abad, Jorge ; Basagaña, Maria ; Padró, Clara ; Carabias, Lídia ; Pardo, Laura ; Roger, Albert ; Cardona Peitx, Gloria ; Rosell, Antoni ; Navarro, Juan ; Martínez-Rivera, Carlos ; Garcia-Olivé, Ignasi ; Cruz, Paula ; Martínez-Colls, Mimar

BACKGROUND:

Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim of this study was to describe the clinical features of complete responders versus non-complete responders to long-term treatment with biologics in patients with severe asthma attended in routine daily practice.

METHODS:

Data of a cohort of 90 patients with severe asthma who were treated with biologics (omalizumab, benralizumab, and mepolizumab) for at least 12 months and were followed up to March 2022. Data recorded included clinical characteristics and effectiveness of treatment (exacerbation, Asthma Control Test [ACT] score, lung function, use of maintenance oral corticosteroids [mOCS]), FeNO, and blood eosinophils at baseline, at 12 months, and at the end of follow-up. Complete response is considered if, in addition to not presenting exacerbations or the use of mOCS, the ACT score was >20 and, the FEV₁ >80% predicted.

RESULTS:

An improvement in all asthma control parameters was observed after 12 months of treatment and a mean follow-up of 55 months. After 12 months of treatment 27.2% of patients met the criteria of complete response and this percentage even increased to 35.3% at the end of follow-up. Long-term complete response was associated to better lung function with mepolizumab and omalizumab treatment and to less previous exacerbations in the benralizumab group. The main cause of not achieving a complete response was the persistence of an airflow obstructive pattern.

CONCLUSIONS:

This study shows that omalizumab, benralizumab, and mepolizumab improved the clinical outcomes of patients with severe asthma in a clinic environment with similar effect sizes to RCTs in the long term follow-up. Airflow obstruction, however, was a predictor of a non-complete response to biologics.

News (Medical) associated with Benralizumab

19 Dec 2024

·www.businesswire.com

Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases

PHILADELPHIA--( BUSINESS WIRE )--Tolerance Bio, Inc., a biopharmaceutical company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2 million seed financing round. Tolerance Bio is developing an allogeneic, or “off the shelf,” induced pluripotent stem cell (iPSC)-based thymus cell therapy platform as well as pharmacological thymus therapies to address immune-mediated diseases. These diseases are caused by abnormalities in immune tolerance, including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies. The Company announced the completion of its seed financing round with the addition of Pacific 8 Ventures to the previously announced syndicate led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners, and individual biotechnology investors. To support the Company’s research and development (R&D) initiatives, Tolerance Bio also announced the formation of its Scientific Advisory Board (SAB). “ The Tolerance Bio team is humbled by the exceptional advisors and investors supporting our mission to preserve, restore and manipulate the thymus to address immune diseases and potentially increase longevity,” said Francisco Leon, M.D., Ph.D., Co-Founder and Chief Executive Officer of Tolerance Bio. “ Each advisor is a leader in their respective fields, providing the Company with unbiased insights and guidance as we advance our programs in immunology, oncology, and beyond. We are incredibly excited by the opportunities lying ahead.” Tolerance Bio’s SAB is comprised of the following members: Dr. Holger Russ, Ph.D. , is the Scientific Co-Founder of Tolerance Bio and its SAB Chairman. Dr. Russ is a pioneer in stem-cell derived thymic and beta cell generation. He is an Associate Professor in the Department of Pharmacology and Therapeutics at the Diabetes Institute of the University of Florida. He is also an Honorary Senior Research Fellow at the Institute of Metabolism & Systems Research at the University of Birmingham in the UK. Dr Russ’s research focuses on the generation of functional human thymic and pancreatic islets from pluripotent stem cells. He has made significant contributions to the field of regenerative medicine and is a co-inventor on eight patents in this area. Dr. Megan Sykes, M.D., is the Michael J. Friedlander Professor of Medicine and Professor of Microbiology & Immunology and Surgical Sciences (in Surgery) at Columbia University. She is Director of the Columbia Center for Translational Immunology, Director of Research for the Transplant Initiative, and Director of Bone Marrow Transplantation Research at Columbia University Medical Center. Dr. Sykes has published more than 500 papers and book chapters during her research career, focusing on hematopoietic cell transplantation, organ allograft tolerance induction, xenotransplantation tolerance, and Type 1 diabetes. She has developed novel strategies for achieving GVL effects without GVHD following hematopoietic cell transplantation (HCT). One such approach provided safety and efficacy data in clinical trials of non-myeloablative haploidentical HCT that permitted the use of HCT for the intentional achievement of organ allograft tolerance in humans. Her work on xenogeneic thymic transplantation for tolerance induction has been extended into non-human primate and human studies. She has used mixed chimerism to reverse autoimmunity while replacing destroyed islets of Langerhans in Type 1 diabetes and developed novel “human immune system (HIS) mouse” models that allow personalized analysis of the pathogenesis of human immune disorders such as Type 1 diabetes. She has also used the HIS mouse model to understand human T cell repertoire development and assess the impact of stem cell-derived human thymic epithelial cells on human T cell development in a porcine thymus. Dr. Sykes is the Past President of the International Xenotransplantation Association, was President of the Federation of Clinical Immunology Societies (FOCiS) from 2022-2024, a recipient of the Medawar Prize, and a member of the National Academy of Medicine. Dr. Camillo Ricordi, M.D., FNAI, is a Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Chief of the Division of Cellular Transplantation, Department of Surgery, Director of the Cell Transplant Center and Director Emeritus of the Diabetes Research Institute (DRI). Since 1993, he has been the Medical Director of the NIH-funded cGMP Advanced Human Cell and Biologic Product Manufacturing Facility, supporting global research and clinical applications. Dr. Ricordi is renowned for inventing groundbreaking technology to isolate islet cells from the human pancreas, revolutionizing islet transplantation for diabetes treatment. He led the first successful clinical islet allotransplants using purified donor islets, reversing diabetes through intra-hepatic infusion. This transformational procedure is now standard practice in clinical islet transplantation worldwide. In 1993, he joined the University of Miami to lead the DRI and Cell Transplant Center. Among his achievements, Dr. Ricordi led the first successful implantation of a bioengineered endocrine pancreas for patients with severe Type 1 Diabetes and chaired the NIH Phase 3 trial on islet transplantation. Currently, he serves as Chairperson of the International Steering Committee and Principal Investigator for two stem cell-derived islet transplant trials. A founding president of key professional organizations, Dr. Ricordi has received numerous accolades, including the World Prize in Surgery, the American Diabetes Association’s Outstanding Scientific Achievement Award, the Leonardo Da Vinci Award, and induction into the National Academy of Inventors. His extensive contributions include over 1,170 publications, 58,000 citations, 28 patents, and the bestselling book The Healthspan Code . Dr. Jerome Ritz, M.D. ’s research focuses on immune reconstitution after hematopoietic stem cell transplantation, cellular therapies, and cancer immunotherapy. Dr. Ritz has co-authored more than 450 scientific publications in peer-reviewed journals and contributed to numerous presentations at leading scientific conferences. From 1996 until June 2024, Dr. Ritz was Executive Director of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) at the Dana Farber Cancer Institute in Boston, Massachusetts. This GMP facility manufactures a variety of cellular products, including genetically modified hematopoietic stem cells, CAR T cells, NK cells, regulatory T cells, invariant NKT cells, and cancer vaccines for patients enrolled in early phase clinical trials. He is a Professor of Medicine at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, and continues to lead a research team at the Dana-Farber Cancer Institute. Dr. Manasi Jaiman, M.D., MPH , is the global, mission-driven Chief Medical Officer of Aardvark Therapeutics, and an expert on cell therapy clinical development. Dr. Jaiman advances breakthrough therapies through the integration of medicine and technology, drawing from 15 years of clinical development, device development, regulatory filings, direct patient care, and scientific research. She was the Chief Medical Officer of ViaCyte, a beta cell therapy company acquired by Vertex in 2022. Through her expertise in stem cell therapy disease and diabetes, she developed the world’s first-in-human protocol using gene-edited cells in a medical device for Type 1 diabetes and successfully executed the clinical trials. Dr. Jaiman also developed the first outpatient clinical trial to study a bi-hormonal artificial pancreas in adults and pediatrics at MassGeneral Hospital, then led clinical trials utilizing the bionic pancreas device, now used at Beta Bionics. Dr. Roland Kolbeck, Ph.D. , is co-owner and the Chief Scientific Officer of Spirovant and an expert on biologic therapeutics in immune diseases. Dr. Kolbeck is an accomplished biotech executive specializing in respiratory sciences and drug discovery. His career spans more than 20 years of research and executive leadership experience, including Vice President and Head of Respiratory, Inflammation, and Autoimmune research at MedImmune/AstraZeneca. At MedImmune, he led the development of FASENRA®, AstraZeneca’s first biological for the treatment of severe eosinophilic asthma, and contributed to the spinout of six pre/clinical-stage autoimmune assets. Previously, he held senior scientific roles at Peptimmune and Millennium Pharmaceuticals. Dr. Kolbeck also served as an Associate Professor in the Department of Pathology and Molecular Medicine at McMaster University from 2014-2022. He earned a PhD from the University of Regensburg and Max Planck Institute of Neurobiology, Munich. About Tolerance Bio, Inc. Tolerance Bio, Inc., is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases. The Company is based in Philadelphia, PA. For more information, visit www.tolerancebio.com or follow us on LinkedIn . About Pacific 8 Ventures Pacific 8 Ventures is a venture fund focusing at the nexus of new technology platforms and medicine. Pacific 8 Ventures typically backs transformative biotech and healthcare founders at the early stages. For more information, please visit: www.pac8.com

Phase 3Cell TherapyImmunotherapyExecutive Change

10 Dec 2024

·www.drugs.com

Benralizumab Beneficial for Eosinophilic Exacerbations of Asthma, COPD

TUESDAY, Dec. 10, 2024 -- Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The Lancet Respiratory Medicine . Sanjay Ramakrishnan, M.B.B.S., from the University of Western Australia in Perth, and colleagues enrolled patients with blood eosinophil counts of ≥300 cells/µL at the time of an exacerbation of asthma or COPD and randomly assigned them to receive acute treatment with prednisolone 30 mg once daily for five days and 100 mg benralizumab subcutaneous injection once (BENRA plus PRED group; 52 patients); placebo tablets for five days plus 100 mg benralizumab subcutaneous injection once (BENRA group; 53 patients); or prednisolone 30 mg once daily for five days plus placebo subcutaneous injection once (PRED group; 53 patients). The proportion of treatment failures over 90 days and total visual analog scale (VAS) symptoms at day 28 were compared in the pooled BENRA groups and the PRED group. The researchers found that treatment failures occurred in 74 and 45 percent of patients in the PRED and pooled BENRA groups, respectively, at 90 days (odds ratio, 0.26). The total VAS mean difference was 49 mm at day 28, favoring the pooled BENRA groups. No fatal adverse events occurred, and benralizumab was well tolerated. "The ABRA [Acute exacerbations treated with BenRAlizumab] study is the first trial to target the eosinophilic treatable trait, during exacerbations," the authors write. "This study shows that benralizumab is effective as an acute treatment of eosinophilic exacerbation." Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca, which manufactures benralizumab and funded the study. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

29 Nov 2024

·pmlive.com

UK researchers uncover first new asthma and COPD attack treatment in 50 years

A UK study has shown that a drug currently used to treat severe asthma could be re-purposed for use in emergency settings, potentially representing the first new treatment for asthma attacks in 50 years. The phase 2 ABRA study, led by scientists from King’s College London and sponsored by the University of Oxford, found that a single dose of AstraZeneca’s benralizumab could be more effective when injected at the point of exacerbation compared to currently used steroid tablets. The trial randomised patients at high risk of an asthma or chronic obstructive pulmonary disease (COPD) attack to receive benralizumab injection, standard-of-care prednisolone, or benralizumab plus prednisolone. Results published in The Lancet Respiratory Medicine showed that respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better with benralizumab after 28 days, and that four times fewer patients in the benralizumab group failed treatment compared to prednisolone after 90 days. The research, conducted with support from AstraZeneca UK, also showed that treatment with benralizumab took longer to fail, meaning fewer visits to a doctor or hospital for patients, and the drug was associated with an improvement in quality of life. Benralizumab is already authorised under the brand name Fasenra as a maintenance treatment for severe eosinophilic asthma and is designed to target specific white blood cells called eosinophils. More than one billion people globally are affected by asthma and COPD, a chronic respiratory disease, with eosinophilic exacerbations accounting for up to 30% of COPD flare-ups and almost 50% of asthma attacks. Steroids such as prednisolone can reduce inflammation in the lungs but have severe side effects, such as diabetes and osteoporosis, and many patients fail treatment. Lead investigator of the trial, Mona Bafadhel, King’s Centre for Lung Health said the findings could be a “game changer for people with asthma and COPD”. She said: “Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets, which is the only treatment currently available.” The researchers are now hoping to launch a two-year phase 3 trial of the drug in 2025.

Phase 2Phase 3Clinical Result

100 Deals associated with Benralizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09874	Benralizumab	R03DX10	DB12023

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Churg-Strauss Syndrome	US	AstraZeneca AB	17 Sep 2024
Severe asthma	US	AstraZeneca AB	17 Sep 2024
Eosinophilic Asthma	EU	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	IS	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	LI	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	NO	AstraZeneca AB	08 Jan 2018
Asthma	US	AstraZeneca AB	14 Nov 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sinusitis	NDA/BLA	US	AstraZeneca PLC	14 Mar 2022
Eosinophilic Enteropathy	Phase 3	US	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	JP	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	BR	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	IT	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	NL	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	PL	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	ES	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	UA	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	VN	AstraZeneca PLC	18 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05384938 (FAST, CTgov)	Phase 4	Asthma	139	Benralizumab	ozvigjmoby(zvtjxerghw) = znsexuwmbm oyidqoiecg (ckbkkqulge, dwwzovfjhs - lwqgthxvum) View more	-	11 Dec 2024
NCT04612790 (FJORD, CTgov)	Phase 3	Pemphigoid, Bullous	67	Benralizumab (DB Period: Benralizumab)	idfawnrulg(ssshjardfk) = dszzuucnne ieptktbqpk (tehfhlnqwy, qlrvprkwnc - zxfgklvrtx) View more	-	29 Nov 2024
				placebo+benralizumab (DB Period: Placebo)	idfawnrulg(ssshjardfk) = wqwnwlbhyy ieptktbqpk (tehfhlnqwy, fjlsjennuk - wsmtdxkjpk) View more
NCT04098718 (Pubmed) Manual	Phase 2	Pulmonary Disease, Chronic Obstructive \| Eosinophilic Asthma	158	benralizumab	eekiildlgm(kirbilvevm) = The 28-day total VAS mean difference was 49 mm (95% CI 14-84; p=0·0065), favouring the pooled-BENRA group. buynvaujna (uwmoeobkla ) View more	Positive	27 Nov 2024
				benralizumab
NCT01928771 \| NCT01914757 (FDA_CDER) Manual	Phase 3	Asthma	-	FASENRA (SIROCCO)	ekfvdhtczv(wobcuwliyb) = zgdgyfnemi pmbeufbyma (pxhszzcagt )	Positive	17 Sep 2024
				Placebo (SIROCCO)	ekfvdhtczv(wobcuwliyb) = mpjdpicuig pmbeufbyma (pxhszzcagt )
NCT04157348 (MANDARA, FDA_CDER) Manual	Phase 3	Churg-Strauss Syndrome	140	FASENRA	zvannyigex(hscbjchpuu) = hfdehtjbpq euoudrvbmt (ztpqjnobql ) View more	Non-inferior	17 Sep 2024
				Mepolizumab	zvannyigex(hscbjchpuu) = ygciwnnjly euoudrvbmt (ztpqjnobql ) View more
NCT03186209 (CTgov)	Phase 3	Asthma	695	Placebo	zuijyfwzyw(wosjhazzhl) = eeositnjni vymsdkbnzr (kjxqhqvonw, ccqeylfapn - kxibxdmfvm) View more	-	24 Apr 2024
NCT04612725 (ARROYO, CTgov)	Phase 2	Chronic Urticaria	159	Benralizumab (Benralizumab 30 mg)	ihyqrpqoqb(jbnkuauovx) = rbzeqfbllz ahhdvxgajc (nwhkjfxefb, tkgwjubtnf - holjhcbrus) View more	-	13 Mar 2024
				Benralizumab (Benralizumab 60 mg)	ihyqrpqoqb(jbnkuauovx) = zctawnejlu ahhdvxgajc (nwhkjfxefb, gcybcmstpg - lafohrqaud) View more
NCT04305405 (TATE study, Pubmed) Manual	Phase 3	Eosinophilic Asthma Add-on blood eosinophil count	28	Benralizumab 10 mg/<35 kg	pixjyxtftm(muyidieovo) = dfsktnoiex twnvzwredr (ngsveskiov ) View more	Positive	01 Mar 2024
				Benralizumab 30 mg/≥35 kg	pixjyxtftm(muyidieovo) = uwhustdidb twnvzwredr (ngsveskiov ) View more
NCT04157348 (MANDARA, AAAAI2024) Manual	Phase 3	Churg-Strauss Syndrome	-	Benralizumab	dpplpqpevk(gzcstygxjw) = zfurqwigue yuppacvzva (sfzwcocykw ) View more	Positive	23 Feb 2024
				Mepolizumab	dpplpqpevk(gzcstygxjw) = qvqmgmygpx yuppacvzva (sfzwcocykw ) View more
NCT04157348 (MANDARA, Pubmed \| Br Dent J) Manual	Phase 3	Churg-Strauss Syndrome	140	Benralizumab	hdzbueficp(ijpiybqspz) = vdpfkicwed nkgsuekhpf (vpcbockbdh ) View more	Non-inferior	23 Feb 2024
				Mepolizumab	hdzbueficp(ijpiybqspz) = jakziufjwo nkgsuekhpf (vpcbockbdh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis